This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 2 EPO patents. Top assignee: Shizuoka Prefecture. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Tohru Mochizuki: Innovator in Cancer Diagnosis
Introduction
Tohru Mochizuki is a notable inventor based in Sunto-gun, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the detection of certain types of cancer. His innovative work has led to the development of a patented method that enhances the accuracy of cancer diagnosis.
Latest Patents
Tohru Mochizuki holds a patent for a biomarker used in the diagnosis of extrahepatic bile duct carcinoma, intrahepatic bile duct carcinoma, or gallbladder carcinoma. The objective of this invention is to provide a method for collecting highly accurate data for diagnosis. This method is particularly useful in determining the presence or absence of these types of cancer. The patent describes a kit that detects the concentration of CEACAM1 in a blood sample. If the concentration is higher than that found in a non-carcinoma control subject, it indicates a high possibility of cancer.
Career Highlights
Throughout his career, Tohru Mochizuki has worked with various organizations, including Shizuoka Prefecture and Shizuoka Prefectural University Corporation. His experience in these institutions has contributed to his expertise in medical research and innovation.
Collaborations
Tohru Mochizuki has collaborated with notable colleagues such as Keiichi Ohshima and Keiichi Hatakeyama. Their joint efforts have further advanced the research and development of diagnostic methods in the medical field.
Conclusion
Tohru Mochizuki's contributions to cancer diagnosis through his innovative patent demonstrate his commitment to improving medical technology. His work has the potential to significantly impact the early detection and treatment of cancer, ultimately benefiting patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile